GoKawiilModerna, Merck report mRNA melanoma vaccine cuts death or recurrence 42%
Moderna and Merck announced that their personalized mRNA melanoma vaccine, combined with Merck's Keytruda, reduced the risk of death or cancer recurrence by 42% compared to Keytruda alone in a Phase 3 trial of 1,137 patients with stage IIB-IV melanoma. The companies released top-line results early after an oncology news outlet broke an embargo ahead of a scheduled presentation at the European Society of Medical Oncology conference in Madrid, with full data set for publication in the New England Journal of Medicine.
GoKawiil's interpretation of the reporting above, not reported fact.
The companies are already in discussions with regulators, suggesting a path toward approval that could make personalized cancer vaccines a mainstream treatment option. Moderna CEO Stéphane Bancel framed the result as validation of mRNA technology's broader potential in oncology, a claim that, if borne out by further trials, could reshape how cancer therapies are designed around individual tumors rather than standardized drugs.
- Trial showed a 42% reduction in death or recurrence risk versus standard treatment alone
- Vaccine is personalized to each patient's tumor and used alongside Merck's Keytruda
- Full results are headed for New England Journal of Medicine publication as regulatory talks begin
Source: arstechnica.com, 2026-10-22
Published there as: “Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%”
Read the original report → The summary and analysis above are GoKawiil's own, written from reporting by the source above. Facts and quotes belong to the original publisher.